Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Fashion & brands

Headache for Reckitt Benckiser as like-for-like sales flat in first quarter reflecting challenging market conditions

The FTSE 100-listed firm reported total sales of £2.643bn for the first quarter of 2017, up 15% on the year earlier at both actual and constant exchange rates, but unchanged on a like-for-like basis which was below forecasts for growth of u

Consumer products group Reckitt Benckiser PLC (LON:RB.) saw its shares drop in early trading after it said its like-for-like sales were flat in the first quarter reflecting challenging market conditions as it progresses a strategic review of its food business and an expansion in to the US baby food industry.

In a trading update, the FTSE 100-listed firm reported total sales of £2.643bn for the first quarter of 2017, up 15% on the year earlier at both actual and constant exchange rates, but unchanged on a like-for-like basis which was below forecasts for growth of up to 0.9%.

Reckitt said a continued strong performance from its Health division led by its Mucinex cold and flu medicine and Durex sexual health products was offset by headwinds for its Scholl/Amopé footcare products, which impacted overall performance.

READ: Reckitt confirms plans for food arm strategic review

CLICK HERE: For a daily round-up of all the Proactive news

In early trading, Reckitt shares were 1.4%, or 100p lower at 7,175p.

However, in a note to clients on Reckitt, Whitman Howard analyst Chris Wickham noted that although the reported flat like-for-like growth was beneath the company polled consensus forecast there was an “element of distortion” in the poll due “to one outlying estimate.”

He added that a “sluggish start to the year was anyway well flagged “.

The analyst reiterated a ‘buy’ rating and 9,000p price target on Reckitt.

Rakesh Kapoor, chief executive officer of the Dettol disinfectants to Neurofen painkillers group, said: "Our Q1 results are in line with expectations as macro conditions remain challenging. Against this backdrop our underlying business remains strong.”

He added: “I expect our growth trajectory to improve as we progress through the year and we remain on track to achieve our full year net revenue target of +3% LFL growth*.

Strategic review of Food business continuing

Earlier this month, Reckitt confirmed it had begun a strategic review of its food business, which includes French's, the top-selling US mustard brand.

The foods arm, which had sales last year of £411mln, could fetch more than £2.4bn if sold, according to media reports.

READ: Reckitt in advanced talks on baby food acquisition

A disposal is being considered to help fund its US$16.6bn takeover of US baby food maker Mead Johnson, announced at the start of February.

Kapoor said: “The acquisition of Mead Johnson, to create a global leader in consumer health, is progressing well and we expect completion by the end of Q3.”

He added: “We remain very confident that the strategic direction we are pursuing will continue to drive shareholder value."

-- Adds share price, broker comment --

CLICK HERE: For a daily round-up of all the Proactive news

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK